Beads for blood processing
Provided are beads for blood processing having porous beads and a polymer carried on the surface of the porous beads, wherein: the porous beads are configured from at least one resin selected from the group consisting of acrylic resins, styrene resins, and cellulose resins; and the polymer includes a specific monomer defined in the description as a monomer unit.
1. Beads for blood processing comprising porous beads and a polymer supported on the surfaces of the porous beads, wherein:
the porous beads are composed of at least one resin selected from the group consisting of acrylic-based resins, styrene-based resins and cellulose-based resins,
the polymer includes a zwitterionic monomer as a monomer unit, and
the zwitterionic monomer content is 10 mol % to 30 mol % based on the total monomers composing the polymer.
2. The beads for blood processing according to claim 1 , wherein a proportion of nitrogen atoms on the surfaces of the beads for blood processing is 0.2% to 0.9%, as the percentage of atoms based on the total number of atoms with atomic numbers of 3 to 92.
3. The beads for blood processing according to claim 2 , wherein the porous beads have a cumulative pore capacity for pore sizes of 5 nm to 100 nm of 0.5 cm 3/g or higher and a cumulative pore capacity for pore sizes of 100 nm to 200 nm of 0.2 cm 3/g or lower, wherein the porous beads have a volume-average particle size of 300 μm to 1000 μm, and the beads remove cytokines and high-mobility group box 1 (HMGB1) from blood.
4. The beads for blood processing according to claim 1 , wherein the porous beads have a cumulative pore capacity for pore sizes of 5 nm to 100 nm of 0.5 cm 3/g or higher and a cumulative pore capacity for pore sizes of 100 nm to 200 nm of 0.2 cm 3/g or lower.
5. The beads for blood processing according to claim 1 , wherein the porous beads have a volume-average particle size of 300 μm to 1000 μm.
6. The beads for blood processing according to claim 1 , wherein:
the zwitterionic monomer is at least one selected from the group consisting of monomers represented by following formula (2):
where R 1 is a hydrogen atom or a methyl group, Y is an oxygen atom or —NH—, R 2 is —CH 2 (CH 2 ) q —, q is 1 to 5, R 3 and R 4 are each independently a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R 5 is —CH 2 (CH 2 ) m —, m is 0 to 4 and Z is —COO − or SO 3 − ,
and monomers represented by following formula (3):
where R 1 is a hydrogen atom or a methyl group, Y is an oxygen atom or —NH—, R 2 is —CH 2 (CH 2 ) q —, q is 1 to 5, R 3 , R 4 and R 6 are each independently a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R 5 is —CH 2 (CH 2 ) m — and m is 0 to 4.
7. The beads for blood processing according to claim 6 , wherein in formula (2), R 1 is a methyl group, q is 1 to 3, R 3 and R 4 are each independently a methyl or ethyl group and m is 0 or 1.
8. The beads for blood processing according to claim 6 , wherein the zwitterionic monomer is at least one selected from the group consisting of N-methacryloyloxyethyl-N,N-dimethylammonium-α-N-methylcarboxybetaine, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, [3-(methacryloylamino)propyl]dimethyl(3-sulfopropyl)ammonium hydroxide and 2-(methacryloyloxy)ethyl 2-(trimethylammonio)ethyl phosphate.
9. The beads for blood processing according to claim 1 , wherein the polymer further includes, as a monomer unit, a monomer represented by following formula (4):
where R 7 is a hydrogen atom or a methyl group, R 8 is —CH 2 (CH 2 ) r —, r is 1 to 5, R 9 is —CH 2 C t H 2t+1 and t is 0 to 3.
10. The beads for blood processing according to claim 9 , wherein the polymer is composed of the zwitterionic monomer and the monomer of formula (4).
11. The beads for blood processing according to claim 9 , wherein in formula (4), r is 1 to 3 and t is 0 or 1.
12. The beads for blood processing according to claim 11 , wherein:
the zwitterionic monomer is at least one selected from the group consisting of monomers represented by following formula (2):
where R 1 is a hydrogen atom or a methyl group, Y is an oxygen atom or —NH—, R 2 is —CH 2 (CH 2 ) q —, q is 1 to 5, R 3 and R 4 are each independently a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R 5 is —CH 2 (CH 2 ) m —, m is 0 to 4 and Z is —COO − or SO 3 − ,
and monomers represented by following formula (3):
where R 1 is a hydrogen atom or a methyl group, Y is an oxygen atom or —NH—, R 2 is —CH 2 (CH 2 ) q —, q is 1 to 5, R 3 , R 4 and R 6 are each independently a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R 5 is —CH 2 (CH 2 ) m — and m is 0 to 4.
13. The beads for blood processing according to claim 12 , wherein in formula (2), R 1 is a methyl group, q is 1 to 3, R 3 and R 4 are each independently a methyl or ethyl group and m is or 1.
14. The beads for blood processing according to claim 13 , wherein the zwitterionic monomer is at least one selected from the group consisting of N-methacryloyloxyethyl-N,N-dimethylammonium-α-N-methylcarboxybetaine, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, [3-(methacryloylamino)propyl]dimethyl(3-sulfopropyl)ammonium hydroxide and 2-(methacryloyloxy)ethyl 2-(trimethylammonio)ethyl phosphate.
15. A blood purification device comprising the beads for blood processing according to claim 1 .